Records containing: Refractory Malignant Solid Neoplasm
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2021-08-10MATCH Treatment Subprotocol Y: AZD5363 in Patients With Tumors With AKT Mutations
-
CLINICAL_TRIALS study record update · 2021-06-29MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients With Tumors With Aberrations in the FGFR Pathway
-
CLINICAL_TRIALS study record update · 2021-04-06MATCH Treatment Subprotocol Z1D: Nivolumab in Patients With Tumors With Mismatch Repair Deficiency
-
CLINICAL_TRIALS study record update · 2021-03-03MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations
-
CLINICAL_TRIALS study record update · 2021-02-05MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients With Tumors With HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2020-09-28Phase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
-
CLINICAL_TRIALS study record update · 2020-07-20MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients With Tumors With DDR2 Mutations
-
CLINICAL_TRIALS study record update · 2020-05-05A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma